GRN-529
GRN-529
GRN-529 (/ɡɑːrˈɛn 529/) is a novel peptide that has been studied for its potential therapeutic effects in the treatment of autism spectrum disorder (ASD) and fragile X syndrome (FXS). The compound is a selective antagonist of the metabotropic glutamate receptor 5 (mGluR5), which is implicated in the pathophysiology of these disorders.
Etymology
The term "GRN-529" is a proprietary name given by the pharmaceutical company Pfizer. The "GRN" prefix is an abbreviation of the company's former name, Groton, and the "529" suffix is a sequential number assigned to the compound during its development.
Mechanism of Action
GRN-529 works by selectively blocking the activity of mGluR5, a type of glutamate receptor that plays a key role in neurotransmission. By inhibiting this receptor, GRN-529 may help to normalize the abnormal neurotransmission that is thought to underlie the symptoms of ASD and FXS.
Related Terms
- Autism spectrum disorder: A range of conditions characterized by challenges with social skills, repetitive behaviors, speech and nonverbal communication.
- Fragile X syndrome: A genetic disorder causing intellectual disability, behavioral and learning challenges and various physical characteristics.
- Metabotropic glutamate receptor 5: A type of receptor in the brain that is involved in neurotransmission and is a target for certain drugs used to treat neurological and psychiatric disorders.
- Peptide: A short chain of amino acids, typically comprising 2-50 amino acids. Peptides are smaller than proteins and can be absorbed by the body more easily.
External links
- Medical encyclopedia article on GRN-529
- Wikipedia's article - GRN-529
This WikiMD dictionary article is a stub. You can help make it a full article.
Languages: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski